Financial Performance - Q2 2025 revenue increased to $56.7 million, representing an 18.3% year-over-year growth[12,22] - Q2 2025 gross margin was 74.2%, a 0.4% increase compared to 2024[24] - Net income for Q2 2025 was $0.6 million, compared to a loss of $1.9 million in Q2 2024[26] - Adjusted EBITDA for Q2 2025 was $9.3 million, compared to $5.6 million in Q2 2024[26] - Operational cash flow increased by $7.8 million, from $28.1 million on March 31, 2025, to $35.9 million on June 30, 2025[28] Business Growth & Development - High Potential (HiPo) accounts yielded approximately 70% of year-over-year revenue growth year-to-date[12] - HiPo accounts have yielded a 21% year-over-year increase in average account productivity year-to-date[12] - The company added approximately 10 million estimated additional covered lives in Q2 via BCBS policy changes, with approximately 17 million estimated new lives year-to-date[14] Guidance - The company raised its full-year 2025 revenue growth guidance to at least 17%, or $219 million[30]

Analyst Presentation Helen Giza CEO & Chair of the Management Board Martin Fischer CFO August 5, 2025 Q2 2025 IR Conference Call Safe harbor statement: In this Safe harbor statement, "the Company" and "Fresenius Medical Care" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements ...

Q2 2025 Financial Performance - Consolidated revenues reached $1686 million, a 5.7% increase year-over-year, or 4.6% on a foreign exchange (FX) neutral basis[6] - Insights revenues grew by 4.2% to $1319 million, or 3.3% on an FX neutral basis, with a contribution margin of 73.9%[6] - Conference revenues increased by 13.6% to $211 million, or 12.0% on an FX neutral basis, boasting a contribution margin of 57.4%[6] - Consulting revenues rose by 8.8% to $156 million, or 6.5% on an FX neutral basis, with a contribution margin of 39.6%[6] - Adjusted EBITDA increased by 6.6% to $443 million, with an Adjusted EBITDA margin of 26.3%[6] - Adjusted EPS grew by 9.6% to $3.53[6] - Free cash flow was $347 million[6] Contract Value Growth - Global contract value (CV) increased by 4.9%[6] - Global Technology Sales CV grew by 3.6% to $3800 million[6] - Global Business Sales CV increased by 9.2% to $1200 million[6] Updated 2025 Guidance - The company projects consolidated revenues of at least $6455 billion[7] - Adjusted EBITDA is expected to be at least $1515 billion[7] - Adjusted EPS is projected to be at least $11.75[7] - Free cash flow is anticipated to be at least $1145 billion[7]

Financial Highlights - All-time high 2Q revenue of $1.8 billion[6] - Highest 2Q Adjusted EBIT margin of +10.5% over the last 10 years[6] - Backlog reached a new record of $29.7 billion[6] - Adjusted Net Results excludes Eve is -$5 million[49] - Shareholder remuneration: Dividends of R$51.4 million and Interest on Equity of R$142.8 million[53] Operational Performance - 2Q deliveries were 30% higher year-over-year[6] - Book-to-bill ratio is around 2x across all business units[6] - Commercial Aviation revenue increased by 4% year-over-year with an EBIT of $25 million[18] - Executive Aviation revenue increased significantly by 64% year-over-year with an EBIT of $80 million[21] - Defense & Security revenue increased by 18% year-over-year with an EBIT of $20 million[25] - Services & Support revenue increased by 13% year-over-year with an EBIT of $71 million[27] Strategic Developments - SAS ordered 45 E195-E2 aircraft, with 10 optional units[7] - SkyWest purchased 60 E175 aircraft, with 50 additional options[7] - Portugal made its 6th KC-390 purchase, along with 10 new options, and Lithuania selected the KC-390[7] US Market Focus - Embraer forecasts $21 billion in US imports and $13 billion in exports by 2030, resulting in an $8 billion trade surplus for the US[15]

DORMAN PRODUCTS, INC. could affect the Company's business, reputation, results of operations, financial condition, and stock price is included in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company is under no obligation to, and expressly ...

Financial Performance - Q2 2025 - Total sales increased by 3.3% to $3.24 billion[18, 54], with constant currency growth of 2.7%[15, 19, 22] - Non-GAAP diluted EPS was $1.10, a decrease of 10.6% compared to $1.23 in Q2 2024[15, 18, 54] - Adjusted EBITDA was $256 million, a decrease of 4.8% compared to $268 million in Q2 2024[15, 18, 57] - Global Distribution and Value-Added Services Group sales grew by 2.4% in constant currency[15, 22] - Global Specialty Products Group sales grew by 3.3%[15, 22] - Global Technology Group sales grew by 6.6%[15, 22] Segment Performance - U S dental merchandise sales decreased 1.2%[22] - International dental merchandise constant currency sales grew 0.5%[22] - U S Medical sales grew 6.3% including acquisitions[22] Guidance and Strategy - The company maintains 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94[12, 46, 48] - 2025 Adjusted EBITDA is expected to grow in the mid-single digits versus 2024 Adjusted EBITDA of $1.1 billion[46] - Total sales growth for 2025 is projected to be between 2% and 4%[12, 48]

Financial Performance - Diluted EPS was $1.86, while adjusted EPS was $1.90, a decrease of 1% year-over-year[5] - Performance Chemicals segment EBIT reached $57 million, showing a 4% increase year-over-year[5] - Reinforcement Materials segment EBIT amounted to $128 million, a decrease of 6% year-over-year[5] - The company returned $64 million to shareholders through dividends and share repurchases[5] - Cash flow from operations was $249 million, with free cash flow of $188 million[22] - The company expects capital expenditures for fiscal year 2025 to be in the range of $250 million to $275 million[22] Strategic Initiatives - An agreement was announced to acquire Bridgestone's reinforcing carbons plant in Mexico for $70 million[7, 11] - Cabot was awarded a platinum rating from EcoVadis for exceptional sustainability performance for the fifth consecutive year, ranking in the top 1% of companies assessed by EcoVadis globally[8, 14] - Notable growth was achieved in Battery Materials, with a 20% contribution margin improvement driven by differentiated products[7, 15] Outlook - The company reaffirms its adjusted EPS guidance range of $7.15 to $7.50 for fiscal year 2025[38, 41, 46]

Financial Performance - Q2 2025 revenue reached $219 million, a 14% year-over-year increase[26] - Annual Run-rate Revenue (ARR) grew to $875 million, also a 14% year-over-year increase[26] - Net Dollar Retention Rate (NDR) improved to 99%, a 200 bps increase[26] - Average Revenue per User (ARPU) increased by 12% to $111.70[26] - The company is raising full year revenue guidance to $888 to $892 million[21] - Adjusted Free Cash Flow Margin for Q2 2025 was 26%, with a trailing twelve months margin of 14%[35] Customer Growth - Digital Native Enterprise (DNE) customers expanded to 174,000[21] - Scalers+ (>$100K Annual run rate) are growing at 35% and represent 24% of revenue[21] - Higher Spend Customers (Builders, Scalers, and Scalers+) represent 89% of total company revenue[41] Product and Innovation - Launched 60 new features across Cloud and AI stack[22] - General Availability (GA) of DigitalOcean Gradient AI Platform[22] Market Focus - The company focuses on the $140 billion Digital Native Enterprises market[11]

Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Transaction Overview - Blade Passenger division 将以高达 1.25 亿美元的价格出售给 Joby Aviation[9]，这笔交易的价格可能会以现金或 Joby 股票支付[10] - Blade 的医疗部门将保留公开上市资格，并更名为 Strata Critical Medical ("Strata")，成为一家纯粹的合同医疗业务公司[9] - 预计资产剥离在调整后的 EBITDA 和自由现金流方面将保持中性，并得到约 700 万美元的年度企业成本效率的支持[9] Financial Performance (Q2 2025) - Medical 部门收入同比增长 18%[18] - Passenger 部门收入同比下降 13%[13] - Medical 部门调整后的 EBITDA 利润率为 13.4%，同比下降 1 个百分点[18] - Passenger 部门调整后的 EBITDA 同比增长 160 万美元[18] - 短途收入（不包括加拿大）同比下降 6%[18] Medical Segment Growth Drivers - 2018 年至 2024 年，心脏、肝脏和肺移植距离增加了 64%[38] - Blade 在器官移植航空物流领域的市场份额估计约为 30%[40] - 地面运输的总潜在市场为 2 亿美元[46] - 器官配置服务的总潜在市场约为 2.5 亿美元[53] Trinity Air Medical Acquisition Impact - 截至 2024 年 9 月 30 日的 12 个月内，Blade/Trinity Medical 部门的总收入约为 1.42 亿美元，分部调整后的 EBITDA 为 1630 万美元[62]